ASLN Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 apr 2024 @ 22:00):

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients...

Stats
Dagens volum	385 087
Gjennomsnittsvolum	1.23M
Markedsverdi	7.18M
EPS	$-0.780 ( 2024-04-26 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.170
ATR14	$0.00400 (0.88%)

Volum Korrelasjon

Lang: -0.04 (neutral)

Kort: 0.63 (weak)

Signal:(46.53) Neutral

ASLAN Pharmaceuticals Korrelasjon

10 Mest positive korrelasjoner
TYRA	0.946
RCEL	0.946
SHIP	0.943
ASUR	0.943
XLRN	0.942
OPRA	0.94
AMPH	0.939
RDNT	0.934
FLMN	0.934
LFMDP	0.933

10 Mest negative korrelasjoner
GOODN	-0.944
WISH	-0.943
TBIO	-0.935
TREE	-0.934
UPLD	-0.931
MICS	-0.929
GMVD	-0.927
AVGR	-0.925
BAND	-0.925
GOODO	-0.924

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

ASLAN Pharmaceuticals Korrelasjon - Valuta/Råvare

-0.77
( moderate negative )

-0.75
( moderate negative )

0.00
( neutral )

0.68
( moderate )

ASLAN Pharmaceuticals Økonomi

Annual	2023
Omsetning:	$12.00M
Bruttogevinst:	$11.65M (97.10 %)
EPS:	$-2.69

FY	2023
Omsetning:	$12.00M
Bruttogevinst:	$11.65M (97.10 %)
EPS:	$-2.69

FY	2022
Omsetning:	$0
Bruttogevinst:	$-331 752 (0.00 %)
EPS:	$-3.68

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.815

Financial Reports:

No articles found.

ASLAN Pharmaceuticals

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.